Trastuzumab emtansine for HER2-positive advanced breast cancer.
about
Media coverage of medical journals: do the best articles make the news?Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionGenomic diversity of colorectal cancer: Changing landscape and emerging targetsMetronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the LiteratureFirst-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Novel approaches to target HER2-positive breast cancer: trastuzumab emtansinePersonalized medicine and treatment approaches in hypertension: current perspectivesCurrent therapeutic strategies of anti-HER2 treatment in advanced breast cancer patientsMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItAutophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerCurrent Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerTargeted therapies with companion diagnostics in the management of breast cancer: current perspectivesABC3 Consensus Commented from the Perspective of the German GuidelinesAntibody-drug conjugates--an emerging class of cancer treatmentMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerChanging strategies for target therapy in gastric cancerDevelopment of Companion DiagnosticsLung cancer biomarkers, targeted therapies and clinical assaysBreast cancer brain metastases: the last frontierGastric cancer: The times they are a-changin'Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerInfluence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesPARP inhibitors in the management of breast cancer: current data and future prospectsDysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistanceAntibody-drug conjugates as novel anti-cancer chemotherapeuticsHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesTargeted therapy for HER2 positive breast cancerImmunotherapy for prostate cancer: recent developments and future challengesApplication of metabolomics in drug resistant breast cancer researchNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyPrimer on tumor immunology and cancer immunotherapyAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicineRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerAn overview of clinical and commercial impact of drug delivery systemsImplications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesProfiling and targeting HER2-positive breast cancer using trastuzumab emtansine
P2860
Q24288686-8E124009-1FEE-425A-8345-3B7B6E51090FQ26738860-EE84D3A2-647E-4B20-A3C6-6AE637EE0728Q26739052-280EAF80-20AD-4E47-9CCE-523E220D4A04Q26745462-F21B7E78-002E-48D7-B492-1AFBD7A2D34CQ26746081-0E23176F-E55B-4EF6-8F2A-CB00F049C3B8Q26747729-5FA6DFDA-4C54-482F-B6EE-1E76DA98B2C1Q26751135-F0D2E489-72BA-4A60-B07D-F10294EE6D68Q26752024-D974DE55-D43D-4300-B8AD-D48E81B2F5EDQ26752780-9773D76C-33E9-42A3-B5F3-F78662542735Q26753162-28819AFB-5958-4DCD-B1C9-A8BB561C2211Q26764987-1A0E04BF-E74B-45C2-9BF5-6E830DE14A70Q26768119-675EB311-7295-4CE7-93E8-120888AF6BCCQ26768665-1141424E-C1C2-4A43-BA01-C3543D7B046DQ26770312-B6F2FFF0-F1CA-4850-AC60-94CAB5BA17CDQ26772969-1B2C2550-E08C-4E1B-A422-B0B2B92934D1Q26774513-2FD9721E-31EB-4F4B-9254-D22424486365Q26774670-88768537-D202-4253-8B94-344A8D6A5C5FQ26775396-45273B11-5395-4591-9FC8-408BD4FF1136Q26775663-A9FC93CA-113F-4F7F-9D66-441554C57C63Q26776195-8D4EEA21-9B23-4AB0-9EAA-095EA9C6F4A6Q26777681-DB788034-9D5A-4E35-A263-0742196F54FEQ26777733-2DCC6F4F-EBA6-4696-B3E7-B4FF46EE1891Q26785612-9C7AB52F-1D7B-4959-8845-15DC63611D9EQ26786243-633F323B-78DB-4C17-B74A-92769246E5B3Q26798352-1A07AFD0-B76F-48BA-8E9D-CB6D932BA707Q26799900-7D7386CC-6857-41CE-A347-FBCF154E490EQ26800175-6382D695-BB50-4F7F-A987-34BFFC39E802Q26822730-89E07D9A-A12F-4F9B-97E7-0FB87CE0C074Q26830496-795C4CDD-1CC3-4231-BF32-CED37A6576D2Q26852388-BA61A8A0-1CA3-4339-9A1A-A034B969F7A1Q26866291-A6C7B98D-8062-4E9F-AE18-C1E6D3A07A02Q26992272-30A3455E-A90E-4AB7-86C9-08E49507AB18Q26993238-EF9A0AB0-E7CB-4134-9A69-4510DAB426E4Q27001126-A792C3D5-0D52-4F19-8404-84BD10A2BC71Q27001994-9BD1F7B1-9993-4131-B0D1-5AC7FDADDEB8Q27003258-8BCCBA80-05DD-4980-A351-73BDC60D6807Q27006181-E008D27E-89F6-4763-A862-2D987B3E30EBQ27007143-398590CD-A592-4CA8-8F6C-999BFCC1EFDCQ27007486-F0856622-1EE9-4885-9126-8EB7AC6D7F41Q27015048-9EAD4C88-78CD-4064-8CEF-A6FCC67C81F4
P2860
Trastuzumab emtansine for HER2-positive advanced breast cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@ast
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@en
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@nl
type
label
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@ast
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@en
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@nl
prefLabel
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@ast
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@en
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@nl
P2093
P2860
P3181
P356
P1476
Trastuzumab emtansine for HER2-positive advanced breast cancer.
@en
P2093
David Miles
Do-Youn Oh
Ellie Guardino
Ian E Krop
José Baselga
Kim Blackwell
Liang Fang
Luca Gianni
Manfred Welslau
Mark Pegram
P2860
P304
P3181
P356
10.1056/NEJMOA1209124
P407
P50
P577
2012-11-08T00:00:00Z